Wegovy Weight-Loss Drug Now Available in Pill Form Across the UK

UK Approves First Oral Version of Wegovy Weight-Loss Drug

British regulators have given the green light to a pill-based version of the widely used weight-loss medication Wegovy, marking a significant milestone in obesity treatment. The approval means patients across the UK will soon be able to obtain the tablet form through a prescription, offering an alternative to the injectable version that many have come to rely on.

A More Convenient Option for Patients

Danish pharmaceutical giant Novo Nordisk, which manufactures the drug, says the once-daily tablet could prove far more practical for many users compared to administering a weekly injection. One notable advantage is that the tablets do not require refrigeration, unlike the injectable version — making storage and travel considerably more straightforward for patients.

The Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed its approval, making this the first tablet of its kind to receive clearance from the regulatory body. According to the MHRA, patients should begin on a starting dose of 1.5mg once daily, gradually increasing through 4mg and 9mg to a maximum of 25mg, with at least one month spent at each dosage level. The tablet must be taken on an empty stomach for optimal effectiveness.

Those already receiving private treatment via the 2.4mg semaglutide weekly injection can transition directly onto the 25mg daily tablet form.

NHS Availability Still Pending

Despite regulatory approval, the pill will not be accessible through the NHS in the near term. The National Institute for Health and Care Excellence (NICE), the body responsible for recommending treatments for NHS use, has confirmed that Novo Nordisk has not yet formally submitted an application for consideration. However, NICE noted it is currently engaged in active discussions with the company.

In the meantime, a number of high street and online pharmacies are preparing to offer the tablet through private prescribing services within the coming weeks.

How the Drug Works

Much like its injectable counterpart, the Wegovy pill contains semaglutide — an active compound that mimics the effects of a naturally occurring hormone known as GLP-1. This hormone works by suppressing appetite and slowing the digestive process, helping individuals feel fuller for longer and reducing overall food intake.

Clinical trials have demonstrated the tablets to be both safe and effective, though patients should expect it to take several months before experiencing the full benefits. As with the injection, there is also a risk of weight returning once the medication is discontinued.

Cost and Wider Availability

The exact pricing of Wegovy tablets in the UK has yet to be confirmed. However, when the drug launched in the United States — where it is already on sale — the manufacturer listed the entry-level 1.5mg dose at approximately $149 (around £110) per month.

Olivier Picard, Chair of the National Pharmacy Association, described the approval as a meaningful development, highlighting that it could benefit patients who are unwilling or unable to use injectable treatments. He also suggested that the pill format could help reduce the overall cost of weight management treatment over time. Pharmacies are currently awaiting further official guidance on when the product will be made available to patients.

Important Considerations for Users

Experts stress that GLP-1 medications are intended as a serious medical intervention for obesity — not a cosmetic or short-term solution. Health professionals strongly caution against misusing these drugs for superficial purposes such as achieving a "beach body."

As with any medication, side effects are possible. Commonly reported issues include nausea, vomiting, diarrhoea, and constipation. Patients are also advised to maintain a balanced diet and engage in regular physical activity alongside treatment.

With more than 16 million UK adults — roughly a third of the population — classified as obese, the arrival of an accessible oral treatment option represents a potentially important step forward in tackling one of the country's most pressing public health challenges. Several other pharmaceutical companies are also developing or have already launched competing products in this rapidly expanding market.